Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Cardiology, University Hospital Örebro, Örebro, Sweden.
Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Chest. 2012 Jun;141(6):1431-1440. doi: 10.1378/chest.11-0435. Epub 2011 Oct 20.
Atrial fibrillation (AF) is common in patients with acute coronary syndromes (ACS). We aimed to describe the value of the CHADS(2) (congestive heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke or transient ischemic attack) score as a risk assessment tool for mortality and stroke in patients with ACS, irrespective of the presence or absence of AF.
Consecutive patients with ACS admitted to the coronary care unit were prospectively included in a risk stratification study. We calculated the CHADS(2) scores from the data collected at admission, and all patients were followed until January 1, 2007, or death.
Of 2,335 patients with ACS in this study, 442 (age 71 ± 8 years, 142 women) had AF. Their mean CHADS(2) score was 1.6 ± 1.4 vs 1.0 ± 1.1 in patients without AF (P < .0001). The all-cause mortality at 10 years was strongly associated with the CHADS(2) score in patients with AF (hazard ratio [HR] and 95% CI per unit increase in the six-grade CHADS(2) score, 1.21 [1.07-1.36]; P = .002), but the same association was also present in patients without AF (HR 1.38 [1.28-1.48], P < .0001), after adjustment for potential confounders. The more complicated GRACE (Global Registry of Acute Coronary Events) risk score provided a better prediction for short- and long-term mortality than the simpler CHADS(2) score (P < .0001). Hospitalization for stroke was significantly associated with the CHADS(2) score in patients without AF (but not in those with AF) after adjustment (HR 1.46 [1.27-1.68], P < .0001).
In patients with ACS, AF is associated with poor prognosis. The CHADS(2) score developed for AF has even greater prognostic value in patients who do not have AF, and it may help to identify patients with high risk for subsequent stroke or death and a need for optimization of risk-reducing treatment.
心房颤动(AF)在急性冠状动脉综合征(ACS)患者中很常见。我们旨在描述 CHADS₂(充血性心力衰竭、高血压、年龄≥75 岁、糖尿病、既往卒中或短暂性脑缺血发作)评分作为评估 ACS 患者死亡率和卒中风险的工具的价值,无论是否存在 AF。
连续纳入入住冠心病监护病房的 ACS 患者进行风险分层研究。我们从入院时收集的数据中计算 CHADS₂评分,所有患者随访至 2007 年 1 月 1 日或死亡。
在这项研究中,2335 例 ACS 患者中有 442 例(年龄 71±8 岁,142 例女性)有 AF。他们的平均 CHADS₂评分为 1.6±1.4,而无 AF 的患者为 1.0±1.1(P<0.0001)。10 年全因死亡率与 AF 患者的 CHADS₂评分密切相关(每增加一个 6 级 CHADS₂评分的单位,风险比[HR]和 95%可信区间为 1.21[1.07-1.36];P=0.002),但在无 AF 的患者中也存在同样的相关性(HR 1.38[1.28-1.48],P<0.0001),调整潜在混杂因素后。更复杂的 GRACE(全球急性冠状动脉事件注册)风险评分比简单的 CHADS₂评分能更好地预测短期和长期死亡率(P<0.0001)。调整后,无 AF 的患者中,因卒中住院与 CHADS₂评分显著相关(但在 AF 患者中无相关性)(HR 1.46[1.27-1.68],P<0.0001)。
在 ACS 患者中,AF 与不良预后相关。专为 AF 开发的 CHADS₂评分在不伴 AF 的患者中具有更大的预后价值,它可能有助于识别具有高风险发生后续卒中和死亡的患者,以及需要优化降低风险治疗的患者。